References

[1]       Bray F, Ferlay J, Soerjomataram I, et al. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin, 68(6): 394-424.

[2]       Xie Shanyan and Ren Peng. (2018). Trend analysis and corresponding countermeasures of cervical cancer [J]. Journal of Raditional Chinese Medicine Management, 26(5): 10-12.

[3]       Crow J M. (2012). HPV: the global burden: human papillomavirus (HPV) has become synonymous with cervical cancer, but its actual footprint is much bigger [J]. Nature, 488(7413): S2-S2.

[4]       Reshmi G, Pillai M R. (2008). Beyond HPV: oncomirs as new players in cervical cancer [J]. FEBS Letters, 582(30): 4113-4116.

[5]       Kobayashi T. (2003). [Obstetrics and gynecology] [J]. 61(10): 1787-92.

[6]       De Freitas A C, Gurgel A P A D, Chagas B S, et al. (2012). Susceptibility to cervical cancer: an overview [J]. Gynecologic Oncology, 126(2): 304-311.

[7]       Fang J, Li Y, Zhang J, et al. (2017). Correlation between polymorphisms in microRNA-regulated genes and cervical cancer susceptibility in a Xinjiang Uygur population [J]. Oncotarget, 8(19): 31758.

[8]       Zeng X, Zhang Y, Yue T, et al. (2017). Association between XRCC1 polymorphisms and the risk of cervical cancer: a meta-analysis based on 4895 subjects [J]. Oncotarget, 8(2): 2249.

[9]       Thompson C B. (1995). Apoptosis in the pathogenesis and treatment of disease [J]. Science, 267(5203): 1456-1462.

[10]    Manzo-Merino J, Contreras-Paredes A, (2014). Vázquez-Ulloa E, et al. The role of signaling pathways in cervical cancer and molecular therapeutic targets [J]. Archives of Medical Research, 45(7): 525-539.

[11]    Martini M, De Santis M C, Braccini L, et al. (2014). PI3K/AKT signaling pathway and cancer: an updated review [J]. Annals of Medicine, 46(6): 372-383.

[12]    Katso R, Okkenhaug K, Ahmadi K, et al. (2001). Cellular function of phosphoinositide 3-kinases: implications for development, immunity, homeostasis, and cancer [J]. Annual Review of Cell and Developmental Biology, 17(1): 615-675.

[13]    Yang Y K, Xi W Y, Xi R X, et al. (2015). MicroRNA‑494 promotes cervical cancer proliferation through the regulation of PTEN [J]. Oncology Reports, 33(5): 2393-2401.

[14]    Zhang S, Yu D. (2010). PI (3) king apart PTEN’s role in cancer [J]. Clinical Cancer Research, 16(17): 4325-4330.

[15]    Stewart A L, Mhashilkar A M, Yang X H, et al. (2002). PI3K blockade by Ad-PTEN inhibits invasion and induces apoptosis in radial growth phase and metastatic melanoma cells [J]. Molecular Medicine, 8(8): 451-461.

[16]    Tamura M, Gu J, Matsumoto K, et al. (1998). Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN [J]. Science, 280(5369): 1614-1617.

[17]    Zhang X, Shi H, Tang H, et al. (2015). miR-218 inhibits the invasion and migration of colon cancer cells by targeting the PI3K/Akt/mTOR signaling pathway [J]. International Journal of Molecular Medicine, 35(5): 1301-1308.

[18]    Hales E C, Taub J W, Matherly L H. (2014). New insights into Notch1 regulation of the PI3K–AKT–mTOR1 signaling axis: Targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia [J]. Cellular Signalling, 26(1): 149-161.

[19]    Kim S M, Park J H, Kim K D, et al. (2014). Brassinin induces apoptosis in PC‐3 human prostate cancer cells through the suppression of PI3K/Akt/mTOR/S6K1 signaling cascades [J]. Phytotherapy Research, 28(3): 423-431.

[20]    Jung K H, Yan H H, Fang Z, et al. (2014). HS-104, a PI3K inhibitor, enhances the anticancer efficacy of gemcitabine in pancreatic cancer [J]. International journal of oncology, 45(1): 311-321.

[21]    Slotkin E K, Patwardhan P P, Vasudeva S D, et al. (2015). MLN0128, an ATP-competitive mTOR kinase inhibitor with potent in vitro and in vivo antitumor activity, as potential therapy for bone and soft-tissue sarcoma[J]. Molecular cancer therapeutics, 14(2): 395-406.

[22]    Zhang Y, Guo X, Xiong L, et al. (2014). Comprehensive analysis of microRNA-regulated protein interaction network reveals the tumor suppressive role of microRNA-149 in human hepatocellular carcinoma via targeting AKT-mTOR pathway [J]. Molecular Cancer, 13(1): 253.

[23]    Tsu V, Jeronimo J. (2016). Saving the World’s Women from Cervical Cancer [J]. N Engl J Med, 374(26): 2509-2511.

[24]    Gommans W M, Berezikov E. (2012). Controlling miRNA regulation in disease [J]. Methods Mol Biol, 822: 1-18.

[25]    Podshivalova K, Salomon D R. (2013). MicroRNA regulation of T-lymphocyte immunity: modulation of molecular networks responsible for T-cell activation differentiation and development [J]. Crit Rev Immunol, 33(5): 435-476.

[26]    Fries GR, Zhang W, Benevenuto D, et al. (2019). MicroRNAs in Major Depressive Disorder [J]. Adv Exp Med Biol, 1118: 175-190.

[27]    Sathyanarayanan A, Chandrasekaran K S, Karunagaran D. (2016). microRNA-146a inhibits proliferation migration and invasion of human cervical and colorectal cancer cells [J]. Biochem Biophys Res Commun, 480(4): 528-533.

[28]    Reddy K B. (2015). MicroRNA (miRNA) in cancer [J]. Cancer Cell Int, 15: 38.

[29]    Abba M L, Patil N, Leupold J H, et al. (2017). MicroRNAs as novel targets and tools in cancer therapy [J]. Cancer Lett, 387: 84-94.

[30]    Arroyo J D, Chevillet J R, Kroh EM, et al. (2011). Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma [J]. Proc Natl Acad Sci USA, 108(12): 5003-5008.

[31]    Ma Y, Liang AJ, Fan YP, et al. (2016). Dysregulation and functional roles of miR-183-96-182 cluster in cancer cell proliferation invasion and metastasis [J]. Oncotarget, 7(27): 42805-42825.

[32]    Zhang W, Qian P, Zhang X, et al. (2015). Autocrine Paracrine Human Growth Hormone-stimulatedMicroRNA96-182-183 Cluster Promotes Epithelial-Mesenchymal Transition and Invasion in Breast Cancer [J]. J Biol Chem, 290(22): 13812-13829.

[33]    Wang Fan, Feng Yuzhen, Zhao Huan, Zhou Mengxia. (2013). Advances in Research of miR-183 Family and Cancer. J Int Obstet Gynecol, 40(5): 436-439.

[34]    Qiu Liwei, Wang Li, pan Liuyi, Yang Xuli, Gu Juanjuan, Yang Junling, Yao Dengfu. (2015). Expression of miRNA-183 family in circulating blood of patients with liver cancer and its clinical value. China Cancer Society, China Cancer Society hepatoma Committee, cancer group of oncology branch of Chinese Medical Association: China Cancer Society, 2015: 2.

[35]    Ren Fei, Yao Desheng, Chen Junying. (2015). Serum mirna-574-5p level and its diagnostic value in patients with cervical squamous cell carcinoma [J]. GUANGXI MEDICAL JOURNAL, 37(01): 15-17.

[36]    Rischin D, Narayan K, Oza AM, et al. (2010). Phase 1 study of tirapazamine in combination with radiation and weekly cisplatin in patients with locally advanced cervical cancer [J]. Int J Gynecol Cancer, 20(5): 827-833.

[37]    Bouvard V, Baan R, Straif K, et al. (2009). A review of human carcinogens-Part B: biological agents [J]. Lancet Oncol, 10(4): 321-322.

[38]    Chang Chunhong, Feng Lei, Guan Xiaoqing, et al. (2018). Expression and clinical significance of miR-155 in human papillomavirus positive cervical cancer and cervical intraepithelial neoplasia [J]. Journal of PLA Medical College, 39(03): 243-247.

[39]    Feng Lei, Chang Chunhong, Guan Xiaoqing. (2018). Expression and clinical significance of mirna-10b in patients with cervical cancer [J]. Journal of Modern Laboratory Medicine, 33(01): 52-55.

[40]    Ma Q, Wan G, Wang S, et al. (2014). Serum microRNA-205 as a novel biomarker for cervical cancer patients [J]. Cancer Cell Int, 14: 81.